Our multidisciplinary team aims to provide care and support for patients and their families. Patients are routinely (every three months) seen by specialists in our team. Together with the NeuroCenter Network we coordinate medical, paramedical and social support at home for patients. We also take part in various research activities. These are directed to identify ALS risk genes, new biomarkers for diagnosis and prognosis, and clinical studies to develop suitable treatments. Finally, we are setting up an ALS Registry in the Center Val de Loire.
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.